X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
http://www.pharmafile.com/news/561675/nice-recommends-siponimod-treating-secondary-progressive-ms
https://www.novartis.com/news/media-releases/novartis-data-show-early-treatment-mayzent-siponimod-delays-disability-progression-and-show-benefits-cognitive-performance-patients-secondary-progressive
https://www.reuters.com/article/us-novartis-china-multiple-sclerosis/china-approves-novartis-multiple-sclerosis-treatment-mayzent-idUSKBN22L0C6?feedType=RSS&feedName=healthNews
https://www.reuters.com/article/brief-novartis-says-new-mayzent-data-sho/brief-novartis-says-new-mayzent-data-shows-sustained-effect-in-delaying-disability-idUSFWN2C81DY
http://www.pharmafile.com/news/546905/five-year-data-supports-early-treatment-novartis-mayzent-secondary-progressive-multiple-
https://www.prnewswire.com/news-releases/roches-ocrevus-continues-to-impress-in-the-eu-with-strong-uptake-in-new-start-and-switch-multiple-sclerosis-patient-segments-but-novartis-mayzent-and-ofatumumab-may-threaten-the-brands-long-term-dominance-301037781.html
https://www.globenewswire.com/news-release/2020/01/20/1972512/0/en/Novartis-announces-EU-approval-of-Mayzent-siponimod-for-adult-patients-with-secondary-progressive-multiple-sclerosis-SPMS-with-active-disease.html
https://www.fiercepharma.com/pharma/after-5-blockbuster-nods-2019-novartis-hopes-for-25-more-coming-years
https://www.prnewswire.com/news-releases/diverse-biotech-announces-appointment-of-new-chief-executive-officer-ceo--stella-vnook-300958378.html
https://www.fiercepharma.com/pharma/crowded-ms-market-merck-kgaa-s-mavenclad-now-offsets-rebif-decline
https://www.fiercepharma.com/pharma/novartis-zolgensma-beats-data-woe-payer-resistance-strong-and-high-interest-ceo
https://www.fiercepharma.com/marketing/ectrims-joining-novartis-and-roche-fight-for-ms-shares-merck-kgaa-touts-mavenclad-data
https://endpts.com/jj-phiii-data-promise-drug-launch-into-crowded-ms-market/
https://www.clinicaltrialsarena.com/news/novartis-ofatumumab-phase-iii/
https://www.fiercepharma.com/pharma/novartis-repurposed-cancer-drug-arzerra-outpaces-sanofi-s-aubagio-multiple-sclerosis-trial
https://www.prnewswire.com/news-releases/alliancerx-walgreens-prime-issues-updated-list-of-new-specialty-drugs-300903210.html
https://www.fiercepharma.com/pharma/novartis-gilenya-staves-off-generic-challengers-after-federal-injunction
https://www.fiercepharma.com/pharma/cost-effectiveness-watchdogs-skewer-novartis-ms-drug-mayzent-and-j-j-s-depression-spray
https://www.fiercepharma.com/pharma/novartis-blockbuster-ms-hopeful-mayzent-shows-more-cognitive-function-benefit
https://endpts.com/pushing-hard-for-blockbuster-returns-novartis-finds-phiii-data-to-assert-mayzent-boosts-cognitive-powers-in-ms-patients/
https://www.raps.org/news-and-articles/news-articles/2019/5/fda-raises-concerns-with-novartis-in-clinical-insp
https://endpts.com/blockbuster-to-be-novartis-snags-a-major-win-as-fda-oks-one-of-its-top-3-late-stage-drugs/
https://www.prnewswire.com/news-releases/fda-approves-new-oral-drug-to-treat-multiple-sclerosis-300819107.html
https://endpts.com/novartis-ceo-vas-narasimhan-lines-up-his-late-stage-blockbuster-contenders-mixing-old-favorites-and-add-ons/
https://endpts.com/novartis-bets-prv-on-its-next-big-ms-drug-eyes-us-eu-approvals-in-19/
https://www.biospace.com/article/novartis-published-multiple-sclerosis-trial-data-with-plans-to-file-for-fda-approval/
http://www.pharmatimes.com/news/us,_eu_filings_imminent_for_novartis_ms_therapy_siponimod_1229021
https://www.prnewswire.com/news-releases/phase-iii-data-in-the-lancet-show-novartis-siponimod-significantly-improved-outcomes-in-patients-with-secondary-progressive-ms-300618481.html
Market Place
Share 
